HBM Holdings Ltd.
1.17
EUR
-0.01
(-0.85%)
HBM Holdings Ltd.
GETTEX:6XY
(Gettex)
Recent
price
1.17
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.- Similar Companies
- Business
- HBM Holdings Limited (HKEX: 2142), also known as Harbour BioMed, is a clinical-stage global biopharmaceutical company focused on the discovery, development, and commercialization of novel antibody therapeutics targeting immunology and oncology diseases. The company leverages its proprietary Harbour Mice platform, which generates fully human monoclonal antibodies in both conventional H2L2 (two heavy and two light chain) and heavy chain-only (HCAb) formats, alongside HBICE bispecific technology for immune cell engagers and single B-cell cloning for next-generation biologics. Core products and pipeline assets include batoclimab (HBM9161), a fully human anti-FcRn antibody for myasthenia gravis (gMG), immune thrombocytopenia (ITP), graves' ophthalmopathy (GO), and neuromyelitis optica spectrum disorder (NMOSD), with a BLA accepted by China's NMPA in 2024; porustobart (HBM4003), a next-generation anti-CTLA-4 antibody for solid tumors including melanoma, colorectal cancer (CRC), hepatocellular carcinoma (HCC), and neuroendocrine neoplasms (NEN); HBM9378, a TSLP-targeted antibody for asthma and chronic obstructive pulmonary disease (COPD); HBM1020, a first-in-class anti-B7H7 antibody for solid tumors; HBM1022 targeting CCR8; HBM9014 targeting LIFR; bispecifics such as HBM7020 (BCMA x CD3) for autoimmune diseases and hematologic cancers, HBM7022 (CLDN18.2 x CD3), HBM7008 (B7H4 x 4-1BB), HBM9027 (PD-L1 x CD40), HBM7004 (B7H4 x CD3), and trispecific HBM7026 (BCMA x CD19 x CD3); plus antibody-drug conjugates like HBM9033 (MSLN ADC) and others in preclinical development for solid tumors, CNS disorders, and obesity via Élancé Therapeutics. Founded in 2016 and headquartered in Suzhou, China, with R&D centers in the United States, Europe, and China, the company operates through two segments—Harbour Therapeutics for pipeline advancement and Nona Biosciences for platform-based collaborations—serving global pharmaceutical partners, biotech firms, and academic institutions across Mainland China, the US, Europe, and internationally. Recent developments include a March 2025 global strategic collaboration with AstraZeneca for next-generation multi-specific antibodies, featuring a $105 million equity investment, up to $4.68 billion in milestones, and an innovation center in Beijing, advanced in November 2025; a June 2025 global license for HBM7020 with Otsuka Pharmaceutical excluding Greater China; a January 2025 license for HBM9378/SKB378 with Windward Bio via Kelun-Biotech; February 2025 AI-driven antibody discovery pact with Insilico Medicine; December 2024 Nona Biosciences deals with Kodiak Sciences and Candid Therapeutics; and 2025 interim revenue of US$101.3 million (up 327% YoY) with net profit of US$73 million, reflecting robust platform monetization and pipeline progress including Phase III data for HBM4003 and BLA advancements for HBM9161.